Harbin Gloria Pharmaceuticals (002437) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Harbin Gloria Pharmaceuticals (002437) has a cash flow conversion efficiency ratio of 0.084x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥182.89 Million ≈ $26.76 Million USD) by net assets (CN¥2.18 Billion ≈ $318.68 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 002437 stock market capitalisation for the company's overall valuation and market capitalisation.
Harbin Gloria Pharmaceuticals - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Harbin Gloria Pharmaceuticals's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Harbin Gloria Pharmaceuticals Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Harbin Gloria Pharmaceuticals ranked by their cash flow conversion efficiency. Explore Harbin Gloria Pharmaceuticals cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hangjin Technology Co Ltd
SHE:000818
|
0.173x |
|
Shenzhen Infinova Ltd
SHE:002528
|
-0.364x |
|
Netcare
JSE:NTC
|
0.220x |
|
Artivion Inc
NYSE:AORT
|
0.003x |
|
Rastar Environmental Protection Materials Co.Ltd.
SHE:300834
|
0.021x |
|
Is Yatirim Menkul Degerler AS
IS:ISMEN
|
0.047x |
|
Aevis Victoria SA
SW:AEVS
|
0.037x |
|
Yinbang Clad Material
SHE:300337
|
-0.038x |
Annual Cash Flow Conversion Efficiency for Harbin Gloria Pharmaceuticals (2007–2025)
The table below shows the annual cash flow conversion efficiency of Harbin Gloria Pharmaceuticals from 2007 to 2025. View Harbin Gloria Pharmaceuticals stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.31 Billion ≈ $337.96 Million |
CN¥273.36 Million ≈ $40.00 Million |
0.118x | -43.18% |
| 2024-12-31 | CN¥1.97 Billion ≈ $288.69 Million |
CN¥410.94 Million ≈ $60.13 Million |
0.208x | +29.93% |
| 2023-12-31 | CN¥1.71 Billion ≈ $250.26 Million |
CN¥274.18 Million ≈ $40.12 Million |
0.160x | +4.39% |
| 2022-12-31 | CN¥1.70 Billion ≈ $249.28 Million |
CN¥261.62 Million ≈ $38.28 Million |
0.154x | +10.84% |
| 2021-12-31 | CN¥1.98 Billion ≈ $289.58 Million |
CN¥274.18 Million ≈ $40.12 Million |
0.139x | +1998.19% |
| 2020-12-31 | CN¥1.93 Billion ≈ $282.85 Million |
CN¥12.76 Million ≈ $1.87 Million |
0.007x | -98.28% |
| 2019-12-31 | CN¥1.59 Billion ≈ $232.45 Million |
CN¥610.37 Million ≈ $89.32 Million |
0.384x | +45.20% |
| 2018-12-31 | CN¥4.39 Billion ≈ $642.95 Million |
CN¥1.16 Billion ≈ $170.15 Million |
0.265x | +72.66% |
| 2017-12-31 | CN¥4.25 Billion ≈ $622.28 Million |
CN¥651.80 Million ≈ $95.38 Million |
0.153x | -40.39% |
| 2016-12-31 | CN¥4.05 Billion ≈ $592.15 Million |
CN¥1.04 Billion ≈ $152.26 Million |
0.257x | +27.19% |
| 2015-12-31 | CN¥3.47 Billion ≈ $508.18 Million |
CN¥702.05 Million ≈ $102.73 Million |
0.202x | -6.96% |
| 2014-12-31 | CN¥3.10 Billion ≈ $453.95 Million |
CN¥674.04 Million ≈ $98.63 Million |
0.217x | +18.87% |
| 2013-12-31 | CN¥2.48 Billion ≈ $362.66 Million |
CN¥453.02 Million ≈ $66.29 Million |
0.183x | +109.59% |
| 2012-12-31 | CN¥2.36 Billion ≈ $345.46 Million |
CN¥205.89 Million ≈ $30.13 Million |
0.087x | +49.01% |
| 2011-12-31 | CN¥2.20 Billion ≈ $321.54 Million |
CN¥128.61 Million ≈ $18.82 Million |
0.059x | +10.24% |
| 2010-12-31 | CN¥2.12 Billion ≈ $310.33 Million |
CN¥112.59 Million ≈ $16.48 Million |
0.053x | -91.06% |
| 2009-12-31 | CN¥287.53 Million ≈ $42.07 Million |
CN¥170.82 Million ≈ $25.00 Million |
0.594x | +99.41% |
| 2008-12-31 | CN¥194.04 Million ≈ $28.39 Million |
CN¥57.81 Million ≈ $8.46 Million |
0.298x | -21.12% |
| 2007-12-31 | CN¥138.36 Million ≈ $20.25 Million |
CN¥52.26 Million ≈ $7.65 Million |
0.378x | -- |
About Harbin Gloria Pharmaceuticals
HARBIN GLORIA PHARMACEUTICALS Co., LTD engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. Its products include cardiovascular and cerebrovascular, musculoskeletal, vitamins, electrolyte, diabetes-lowering, analgesics, digestive system and metabolism, anti-infective, and anti-tumor drugs. Harbin Gloria Pharmaceuticals Co., Ltd w… Read more